About the FNIH

$0.91
of every dollar spent
directly supports programs

$1 Billion +
raised since inception

#1
“Charitable Biomedical Research Organization”
by Charity Navigator

14
consecutive years of
“Exceeds Industry Standards”
rating by Charity Navigator

#1
“Organization of the Year”
at Stevie Awards for Women in Business

You and the FNIH

The Foundation for the National Institutes of Health (FNIH) works with partners like you to advance breakthrough biomedical discoveries and improve the quality of people’s lives. As a 501(c)(3) charity chartered by Congress, the FNIH depends on private philanthropy to support vital scientific research, education and training, awards and patient care activities at the National Institutes of Health (NIH), the world’s largest biomedical research agency. The FNIH’s team of scientists, program managers and fundraisers works hand-in-hand with you each day to shape the future of human health.

Read more:
fnih.org/AnnualReport
Dear Friends,

We begin by saying thank you! Thank you for your time, forward-thinking ideas, generous support and dedication to biomedical research.

You equip the FNIH with the essential resources needed to advance transformative biomedical research in support of the mission of the NIH and to have global impact. In 2017, you helped us reach the amazing milestone of raising more than $1 billion since our inception. These private-sector dollars are critical for breakthrough discoveries that improve the quality of people’s lives.

Your generous support allows us to convene large networks of scientific leaders to seek new knowledge and catalyze research collaborations to improve health, lengthen life and reduce illness and disability. These alliances foster innovation and channel resources for maximum impact — achieving results far greater than what can be accomplished by any single organization.

In this 2017 Annual Report, we are delighted to highlight a few examples of the support and commitment of some of our partners and donors. In these vignettes, you will learn about projects that are solving some of the major unanswered questions of biomedical research, training the next generation of clinician-scientists, honoring outstanding scientific achievements and helping NIH patients and their families.

The work that you have supported has allowed the FNIH to be honored and recognized internationally last year. In 2017, the FNIH was named the “#1 Charitable Biomedical Research Organization” by Charity Navigator and earned a Gold Stevie Award for “Organization of the Year.”

So, once again, the FNIH Board of Directors and staff want to recognize the contributions of all of those individuals and organizations that have made our work possible. Thank you for your trust and support and for helping us shape the future of human health. We look forward to working closely with you in the years to come.

Steven M. Paul, M.D.
CHAIRMAN

Maria C. Freire, Ph.D.
PRESIDENT AND
EXECUTIVE DIRECTOR
Individuals

Individuals have the power to address some of the most vexing health challenges of today. Supporting the FNIH with unrestricted donations allows the FNIH to leverage and strategically deploy funds where they are most needed. Further, donors may wish to support specific areas of interest — from research in certain diseases to patient care.

Andrew Lee

At age 22, Andrew Lee is driven. Following his HLRCC diagnosis, Andrew established the not-for-profit Driven to Cure, Inc. He now travels the country attending car events to raise visibility and funding for rare kidney cancers.

In December 2017, Andrew presented a $100,000 check to Maria C. Freire, Ph.D., FNIH President and Executive Director. This donation, in addition to a $200,000 gift made in 2016, will further cutting-edge research on rare kidney cancer conducted by the National Cancer Institute (NCI) at the NIH Clinical Center.

“Thanks to FNIH’s mission, the needed funding can be targeted to the research of rare cancers like HLRCC. We look forward to working with the FNIH in the years ahead to help fund other rare cancers and diseases in order to help more patients,” said Andrew. Learn more at fnih.org/DriventoCure.

“When I was diagnosed with stage 4 HLRCC rare kidney cancer at age 19, I was told I had six to 12 months to live. I was immediately accepted to the HLRCC trial at the NIH in June of 2015. I know and understand there is currently no known cure for HLRCC, but without the research happening today, we would not help those who will be in need tomorrow.”

— Andrew Lee

PRESIDENT OF DRIVEN TO CURE, INC.
The cultural and philanthropic contributions of Buffy Cafritz are ever present around the country, especially just 10 miles north of Washington, D.C. on the NIH campus in Bethesda, MD.

Mrs. Cafritz’s unwavering commitment to the FNIH has supported students, patients and researchers at the NIH for nearly two decades. She and her husband have helped students interested in Parkinson’s disease train with renowned scientists by funding the NIH Medical Research Scholars Program, thus supporting a new generation of clinician-scientists. Mrs. Cafritz also sponsors a room at the Edmond J. Safra Family Lodge just footsteps away from the NIH Clinical Center, so that patients and their families can stay together during treatment.

Mrs. Cafritz and the Buffy and William Cafritz Family Foundation’s commitment to biomedicine extends to research in the laboratory. In 2017, their support created a five-year competitive grant program at the NCI to develop highly innovative approaches and technologies for kidney cancer. Through her dedication to this significant work, Mrs. Cafritz’s presence in biomedical research will be felt for generations to come.

“It has been a pleasure to support the FNIH throughout the years to further pioneering biomedical research, crucial student training and activities that help heroic patients participating in clinical trials. The nimble, yet powerful FNIH team, is making important medical discoveries possible. I am proud to be a part of their work, which will benefit our world far into the future.”

– Buffy Cafritz

HONORARY TRUSTEE, THE JOHN F. KENNEDY CENTER FOR THE PERFORMING ARTS, AND FNIH BOARD MEMBER
Ms. Carol-Ann Harris

Ms. Carol-Ann Harris of Fort Lee, NJ, advances muscular dystrophy research through the CarMollNat Endowment at the FNIH.

“Muscular dystrophy has affected my family for at least seven generations. I felt it was my calling to honor my loved ones by investing in the FNIH so that important research can propel this field forward and help future patients and their families in the years to come.”

– Ms. Carol-Ann Harris

Barbara Lazio, M.D., and Mr. Matthew Scher

Barbara Lazio, M.D., and Mr. Matthew Scher of Olympia, WA further cancer research by donating annually to the FNIH in honor of their mothers, who passed away from the disease.

“After losing some of our closest family members and friends to cancer, we felt we needed to support ongoing research to benefit future cancer patients. There are many charities soliciting funds for cancer research, but we felt by investing in the FNIH, our money would be applied to the most highly vetted and innovative research. We really just want to keep the fire burning, support the innovators, see these baby steps develop into something that can eventually impact a person’s life.”

– Barbara Lazio, M.D.
As lead benefactor of the Edmond J. Safra Family Lodge (Family Lodge), Mrs. Lily Safra has made housing available for about 130,000 adult patients of the NIH Clinical Center and their loved ones since 2005. These brave patients travel with their families from around the world to participate in vital research at the NIH Clinical Center, which is known for its history of medical breakthroughs, including the development of chemotherapy for cancer and the first AIDS treatment.

Located within walking distance of the NIH Clinical Center, this English manor-style residence features 34 spacious guest rooms. Its elegant kitchen, library, fitness and business centers, and gardens, alongside its dedicated onsite team, offer families a home-like place of respite during their time of need. By caring for these courageous families, Mrs. Safra is ensuring crucial biomedical research rapidly progresses to improve the health of current patients and those in the years ahead. Learn more about the Family Lodge at fnih.org/FamilyLodge.

“I know from personal experience how when one person becomes ill, a whole family is affected. By providing a warm and comfortable environment for patients’ families at the Edmond J. Safra Family Lodge, I hope that more people will be able to seek treatment and participate in vital clinical research efforts at the NIH Clinical Center.”

– Mrs. Lily Safra
CHAIRWOMAN OF THE EDMOND J. SAFRA PHILANTHROPIC FOUNDATION AND FNIH BOARD MEMBER
Not-for-Profits and Foundations

Not-for-profit and foundation partners have helped the FNIH orchestrate programs to develop preventive medicines, diagnostic tools and new therapies and to train the next generation of clinician-scientists. Often working closely with government and industry partners, these organizations keep patients top-of-mind — bringing their critical perspective to FNIH programs.

Amgen Foundation and Doris Duke Charitable Foundation

The FNIH supports training programs at the NIH that enable students interested in biomedicine to work closely with some of the world’s leading researchers. These programs are made possible with partners including the Amgen Foundation and the Doris Duke Charitable Foundation.

“By partnering with the FNIH — in addition to institutions such as Harvard, MIT and Cambridge — we are opening the door to ground-breaking research opportunities in biomedical research that continue to advance human health in untold ways. If your mission is to inspire and train the next generation in biomedical research — or to advance scientific breakthroughs into human health — the FNIH needs to be on your short list as an organization worth partnering with.”

— Scott Heimlich, Ed.D.
VICE PRESIDENT, AMGEN FOUNDATION

“By partnering with the FNIH — in addition to institutions such as Harvard, MIT and Cambridge — we are opening the door to ground-breaking research opportunities in biomedical research that continue to advance human health in untold ways. If your mission is to inspire and train the next generation in biomedical research — or to advance scientific breakthroughs into human health — the FNIH needs to be on your short list as an organization worth partnering with.”

— Scott Heimlich, Ed.D.
VICE PRESIDENT, AMGEN FOUNDATION

“Our partnership with the FNIH supports the Medical Research Scholars Program, which gives medical students a hands-on clinical research experience under the guidance of successful scientists. We are proud to support this program as an avenue for igniting in students a passion for research that can translate into a productive, lifelong career as a physician scientist.”

— Betsy Myers, Ph.D.
PROGRAM DIRECTOR FOR MEDICAL RESEARCH, DORIS DUKE CHARITABLE FOUNDATION

“By partnering with the FNIH — in addition to institutions such as Harvard, MIT and Cambridge — we are opening the door to ground-breaking research opportunities in biomedical research that continue to advance human health in untold ways. If your mission is to inspire and train the next generation in biomedical research — or to advance scientific breakthroughs into human health — the FNIH needs to be on your short list as an organization worth partnering with.”

— Scott Heimlich, Ed.D.
VICE PRESIDENT, AMGEN FOUNDATION

“By partnering with the FNIH — in addition to institutions such as Harvard, MIT and Cambridge — we are opening the door to ground-breaking research opportunities in biomedical research that continue to advance human health in untold ways. If your mission is to inspire and train the next generation in biomedical research — or to advance scientific breakthroughs into human health — the FNIH needs to be on your short list as an organization worth partnering with.”

— Scott Heimlich, Ed.D.
VICE PRESIDENT, AMGEN FOUNDATION

“Our partnership with the FNIH supports the Medical Research Scholars Program, which gives medical students a hands-on clinical research experience under the guidance of successful scientists. We are proud to support this program as an avenue for igniting in students a passion for research that can translate into a productive, lifelong career as a physician scientist.”

— Betsy Myers, Ph.D.
PROGRAM DIRECTOR FOR MEDICAL RESEARCH, DORIS DUKE CHARITABLE FOUNDATION

McKnight Brain Research Foundation

The McKnight Brain Research Foundation (MBRF)’s decade-long partnership with the FNIH has expanded understanding of how people think as they age, through co-sponsorship of the Research Partnership in Cognitive Aging and three Cognitive Aging Summits with the National Institute on Aging (NIA).

“This partnership has facilitated exploration of new avenues of potential research within the scientific community, which could lead to the development of pharmacological and behavioral interventions, and ultimately improved outcomes in cognitive health. A very important outcome has also been raising the level of awareness within the scientific community and among the public about the importance of this research and its tremendous value to society in preserving and maintaining cognitive health.”

— J. Lee Dockery, M.D.
CHAIR, BOARD OF TRUSTEES, MBRF
Bill & Melinda Gates Foundation

Addressing some of the world’s most pressing health challenges, including tuberculosis and malaria, requires the proficiency of indomitable scientists backed by excellent project management and stable financial support. For more than a decade, the Bill & Melinda Gates Foundation (Gates Foundation) has worked with the FNIH to develop strong ecosystems that underpin scientific discovery and foster creation of emerging technologies to provide novel solutions to fight disease.

In 2017, among other key accomplishments, this work resulted in the publication of the Guiding Principles for Sponsors and Supporters of Gene Drive Research in Science. Considered an emerging technology, gene drive can be used to promote the preferential inheritance of a beneficial trait, thereby increasing its prevalence in a population. The developers and signatories of these guiding principles are committing to support research of the highest scientific and ethical quality, inspire a transparent approach and back relevant biosafety measures and best practices. Learn more about this work at fnih.org/GeneDrivePrinciples.

The Gates Foundation’s Steven Buchsbaum, Ph.D., reflected on the foundation’s longstanding partnership with the FNIH:

“The FNIH was, in the very early days of the Gates Foundation, a key partner that we chose to first begin investing in basic science for global health. That started with the original Grand Challenges in Global Health, which the FNIH was our key partner in formulating and executing.

Having had the opportunity to see projects evolve and mature over more than a decade, there are a number of them that were called for, selected, invested and nurtured either by the FNIH themselves or jointly with us that are incredibly promising in the sense that they are transformational new tools for global health. One example is the Eliminate Dengue project (now called the World Mosquito Program) and another is the Target Malaria initiative. But perhaps more than that, and harder to measure and directly attribute, is really just the change in the scientific community in the sense of the excitement, attention paid and amount of research that is done on health conditions that affect the majority of the population in the world, but particularly those that are poor and underserved.”
Government agencies are the bedrock of FNIH partnerships. For two decades, the FNIH has worked with federal agencies to build powerful initiatives with the private sector that have changed the way researchers, regulators, doctors and patients understand and treat disease.

Congress chartered the FNIH to raise private funds to support the world’s largest biomedical research agency, the NIH. The FNIH leverages the know-how and resources of the private sector to work with the NIH to tackle complex biomedical challenges. In 2017, the FNIH, NIH, U.S. Food and Drug Administration (FDA) and 12 biopharmaceutical companies launched the historic $220 million Partnership for Accelerating Cancer Therapies (PACT) to better understand how to harness the immune system to attack cancer. Learn more at fnih.org/PACT.

“The FNIH makes it possible for the NIH, as a government facility, to work with the private sector to answer some of the world’s most pressing health questions. Through innovative research partnerships, the NIH and FNIH are able to fuel the biomedical discoveries needed for better diagnosis, prevention, treatment and cure of disease. Working with the FNIH is vital to the research enterprise.”

– Francis Collins, M.D., Ph.D.
DIRECTOR, NIH

A pseudo-colored scanning electron micrograph of an oral squamous cancer cell (white) being attacked by two cytotoxic T cells (red), part of a natural immune response.
Credit: National Cancer Institute / Duncan Comprehensive Cancer Center at Baylor College of Medicine
In October 2017, FNIH Chairman Dr. Steven M. Paul and President and Executive Director Dr. Maria C. Freire presented NIA Director Dr. Richard Hodes with a Charles A. Sanders, M.D., Partnership Award.

“The FNIH offers a great venue to bring together the NIH, FDA, academia and the pharmaceutical industry to conduct robust translational research that will enable more informative and better targeted medical product development.”

– Janet Woodcock, M.D.
DIRECTOR, CENTER FOR DRUG EVALUATION AND RESEARCH, FDA, AND EXECUTIVE COMMITTEE MEMBER OF THE FNIH BIOMARKERS CONSORTIUM

National Institute on Aging

The NIA, under the inspired leadership of Director Richard Hodes, M.D., has been one of the FNIH’s most significant and longstanding partners. Over the past decade, the NIA and the FNIH have developed new collaboration models, governance structures and data-sharing policies for such groundbreaking programs as the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the Accelerating Medicines Partnership (AMP). Dr. Hodes reflected on this partnership with the FNIH:

“The benefit of collaborations, scientific meetings and other support provided to NIH through the Foundation is not limited to the institute or institutes whose work is being facilitated. These efforts galvanize all partners in moving toward shared goals. We have seen this in several areas, most recently in the emergence of the new discipline of geroscience, where Foundation efforts have facilitated conferences that have helped develop new synergy between researchers in the basic biology of aging and scientists focused on specific diseases associated with advanced age, such as cancer and heart disease. This new approach has enhanced the recognition of aging as the critical risk factor underlying disease development in many cases and has fostered new connections among public and private sector scientists seeking to reduce disease risk and improve health for older people.”

U.S. Food and Drug Administration

The FDA, the U.S. regulatory agency for biomedical technologies, is a primary partner actively engaged in FNIH public-private consortia that formulate and lead cutting-edge research programs.

The FNIH Biomarkers Consortium manages many of these programs, which often have regulatory implications. The mission of the Biomarkers Consortium is to discover, develop and seek regulatory approval of biological markers (biomarkers) to support development of new diagnostic tools and drugs within four key areas: cancer, inflammation and immunity, metabolic disorders and neuroscience. In 2017, the Biomarkers Consortium reached several milestones, including the publication of a framework to guide biomarker qualification in Science Translational Medicine, as well as submitting recommendations to the FDA to guide drug development for serious hospital-acquired bacterial infections. Learn more about Biomarkers Consortium projects at fnih.org/BiomarkersConsortium.
Industry partners work with the FNIH to build powerful scientific collaborations that fuel biomedical discovery. By bringing world-class scientists, critical datasets, the latest technology and financial resources to these partnerships, industry helps the FNIH facilitate the exchange of ideas in a pre- or non-competitive environment that would not be possible otherwise.

“I believe that every dollar donated to FNIH will ‘punch above its weight’ in the fight against disease and will open the doors for value-added partnerships to speed the flow of new cures.”

— Freda C. Lewis-Hall, M.D., DFAPA  
EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER, PFIZER, AND FNIH BOARD MEMBER

Pfizer

Pfizer’s sustained commitment to the FNIH spanning two decades has bolstered a suite of biomedical initiatives on topics from genetics to lung cancer, laying the groundwork for important discoveries.

The company’s scientific leadership and financial support to the FNIH have expanded understanding of the genetic causes of common diseases, enabled pediatric testing programs for drugs and increased knowledge of Alzheimer’s and lung cancer, to name a few. It also furthered the careers of research-oriented medical and dental students by sponsoring training at the NIH.

Additionally, Pfizer leaders, including Dr. Freda C. Lewis-Hall, have brought their vision and expertise to the FNIH Board of Directors. “The world is chock-full of promising scientific leads and information that is valuable in the service of patients, and the FNIH is a key conduit in the flow of these ideas,” said Dr. Lewis-Hall. “It’s hard to believe that the FNIH has been operating for just over 20 years, as its become such an important facilitator of the public-private partnerships that ultimately expand the universe of biomedical science, especially the science that can be translated into new therapies and the science that provides a rocket-boost to other medical research endeavors.”
Lilly

Since 2000, Lilly and the FNIH have advanced critical research to increase scientific understanding across multiple diseases, including osteoporosis, lung cancer and Alzheimer’s disease, through 44 projects.

In particular, Lilly played an essential role in the establishment of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), becoming the first company to join the partnership 13 years ago and championing support from other industry representatives. “ADNI has increased our understanding of Alzheimer’s disease (AD) by identifying and validating biomarkers, including specific imaging for tau and amyloid as hallmarks of this disease that indicate the onset and progression of AD,” explained Lilly’s Jan Lundberg, Ph.D. “ADNI’s work helps biopharmaceutical companies like Lilly improve clinical trial design and test new medicines.” Read about ADNI at fnih.org/ADNI3.

Lilly also supports projects within the FNIH Biomarkers Consortium and is a significant proponent of the Accelerating Medicines Partnership (AMP), particularly the AMP-AD and the AMP Type 2 Diabetes projects. “Data from AMP and other FNIH partnerships are guiding our evolving strategy for AD and diabetes drug discovery and development,” said Dr. Lundberg. “Ultimately, that will benefit millions of patients including understanding disease sub-classification and patient stratification signature.” Learn more about AMP at fnih.org/AMP.

Dr. Lundberg continued, “It is essential to encourage the exchange and robust scientific discussion of new ideas. To this end, I would say the number one benefit to Lilly from our investment in FNIH is the foundation’s ability to accelerate biomedical research by creating public-private partnerships where scientists interact and learn from each other across different sectors of the biomedical healthcare system, including regulatory authorities.”

“Public-private partnerships involving the biopharmaceutical industry, NIH and academia have advanced key areas of human disease understanding and the potential for diagnostics and therapies by unifying resources and capabilities and making findings public.”

– Jan Lundberg, Ph.D.

EXECUTIVE VICE PRESIDENT, SCIENCE AND TECHNOLOGY AND PRESIDENT, LILLY RESEARCH LABORATORIES

In October 2017, Lilly Executive Vice President Dr. Jan Lundberg accepted a Charles A. Sanders, M.D., Partnership Award on the company’s behalf.
and thanks each of our valued partners, whose generosity provides the critical resources needed to accelerate scientific discoveries to diagnose, treat and cure the world’s most devastating diseases. Unrestricted gifts allow the flexibility to use donations where they are urgently needed, while restricted gifts serve a specific area of research. Other donors choose to partner and establish funds and endowments to pay tribute to loved ones.
To learn more about ways to give, please select from the following links:

**Partners for Innovation, Discovery and Health Society:**
Learn more at fnih.org/PartnersSociety.

**Legacy Society:**
For questions regarding bequests or estate planning visit fnih.org/PlannedGiving and join others who include the FNIH in their estate plans at fnih.org/LegacySociety.

**Tribute and Memorial Giving:**
Learn more about gifts to honor someone special at fnih.org/TributeGiving.

**Funds and Endowments:**
Contribute to or establish a fund or endowment that advances research in a particular area of interest by searching FNIH programs at fnih.org/Programs.

**Research Programs:**
Find a specific research program to donate to at fnih.org/ResearchPrograms.

For a complete list of donors, funds and endowments, visit fnih.org/AnnualReport. Please call 301.402.4976 or email advancement@fnih.org with questions.
## Our 2017 Donors

### Key
- **Number of Years of Consecutive Giving**
- **Gifts in Kind**
- **Member of the Partners for Innovation, Discovery and Health Society**
- **New Members of the Legacy Society**

### Donors

<table>
<thead>
<tr>
<th>Category</th>
<th>Donor Name</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5,000,000+</td>
<td>Amgen, Inc.</td>
<td>$2,500,000–$4,999,999</td>
</tr>
<tr>
<td></td>
<td>AstraZeneca Pharmaceuticals, LP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bristol-Myers Squibb Company</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Johnson &amp; Johnson</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novartis Pharmaceuticals Corporation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pfizer Inc</td>
<td></td>
</tr>
<tr>
<td>$2,500,000–$4,999,999</td>
<td>Anonymous</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AbbVie Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bill &amp; Melinda Gates Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GlaxoSmithKline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Merck Sharp &amp; Dohme Corp.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Takeda Pharmaceuticals International, Inc.</td>
<td></td>
</tr>
<tr>
<td>$1,000,000–$2,499,999</td>
<td>Anheuser-Busch InBev</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biogen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carlsberg Breweries A/S</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Celgene Corporation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diageo Plc</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EMD Serono, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Michael J. Fox Foundation for Parkinson's Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gilead Sciences, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HEINEKEN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>McKnight Brain Research Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>National Institutes of Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pernod Ricard</td>
<td></td>
</tr>
<tr>
<td>$500,000–$999,999</td>
<td>Buffy Cafritz</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Research Associates, LLC, an affiliate of the Simons Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ann Lurie</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wyeth Nutrition</td>
<td></td>
</tr>
<tr>
<td>$250,000–$499,999</td>
<td>Estate of Jonathan D. Gest</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmaceutical Research and Manufacturers of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Regeneron Pharmaceuticals, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TissueGene, Inc.</td>
<td></td>
</tr>
<tr>
<td>$100,000–$249,999</td>
<td>Arthritis Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bayer HealthCare Pharmaceuticals Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Congress of Neurological Surgeons</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Crescendo Bioscience, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Driven To Cure, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Foundation for AIDS Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genentech, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Norman Hess</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Institut De Recherches Internationales Servier and ADIR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peter and Judy Kovler</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lundbeck</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lupus Research Alliance</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Pew Charitable Trusts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>George Vradenburg Co-Founder USAgainst Alzheimer's</td>
<td></td>
</tr>
<tr>
<td>$50,000–$99,999</td>
<td>Alector</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alzheimer's Association</td>
<td></td>
</tr>
<tr>
<td></td>
<td>American Association for Dental Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Critical Path Institute &amp; the Predictive Safety Testing Consortium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Denali Therapeutics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GE Healthcare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Paul M. Montrone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxford BioDynamics Plc</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Steven and Jann Paul</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ROCHE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Saladax Biomedical, Inc</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fred A. and Donna Seigel</td>
<td></td>
</tr>
<tr>
<td>$25,000–$49,999</td>
<td>Adaptive Biotechnologies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Geoffrey Beene Foundation Alzheimer's Initiative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BioClinica, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Elsevier, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GHR Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Liz and Eric Lefkofsky</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mr. and Mrs. Joel S. Marcus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>National Dairy Council</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ortho Clinical Diagnostics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bill and Giuliana Rancic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rheumatology Research Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Andrew Steinhaus</td>
<td></td>
</tr>
</tbody>
</table>
$10,000–$24,999

23andMe, Inc.
Accelerate Cure/Treatments for Alzheimer's Disease (ACT-AD) 2
American Society for Bone and Mineral Research
Arclon Biotech
Bio-Rad Laboratories, Inc.
Citigroup Inc. 2
Cleary Gottlieb Steen & Hamilton LLP
CogState Ltd 3
Davis Polk & Wardell LLP
DiamiR, LLC 2
James H. and Christina W. Donovan 4
EUROIMMUN AG 6
Andrew and Michelle Feinberg 7
Estate of Linda Founds 8
Estate of Jack Gramlich 7
Illumina, Inc.
Dr. and Mrs. Thomas R. Insel 9
James Jones In memory of Brenda S. Jones
MagQu Co., Ltd. 2
March of Dimes Birth Defects Foundation 2
Steve and Sherry Mayer 10
Medtronic, Inc.

$5,000–$9,999

Martin J. Murphy, Ph.D. and Ann Murphy, Ph.D. 11
Bob and Sally Newcomb 7
Northwestern Medicine
Olink Proteomics
Paul, Weiss, Rifkind, Wharton & Garrison LLP 2
PeopleBio, Inc. 2
Piramal Imaging, GmbH 7
Curt and Linda Rodin 7
Jane M. Sayer, Ph.D. 2
Gerald R. Sigal and Ellen V. Sigal, Ph.D. 8
Solomon H. Snyder, M.D. 2
Society for Immunotherapy of Cancer
Nina K. Solarz 8
SomaLogic, Inc. 2
Russell W. Steenberg and Patricia Colbert 12
Clara J Szekely Foundation Inc. 1
UCB, Inc. 2
Anonymous
AARP
Jeffrey Abrams, M.D.
Alzheimer's Drug Discovery Foundation 5
American Association of Colleges of Nursing
American Diabetes Association 8
AFTD (Association for Frontotemporal Degeneration)
Avanir Pharmaceuticals
Paula L. and William C. Bradley 13
Laura Catena, M.D.
Ralph H. and Karen K. Craft 14
The Geaton & JoAnn DeCesaris Family Foundation, Inc. 1
In honor of Betty DeCesaris
Doris Duke Charitable Foundation 4
Susan E. Finley 15
Fisher Foundation 5
Frederick National Laboratory for Cancer Research
Ernesto I. Freire, Ph.D. and Maria C. Freire, Ph.D. 16
Theodore N. Giovanis, M.B.A. 15
Carol-Ann Harris 5
Home Instead Senior Care
Invitae
Keith R. Leonard, Jr. 17
Lawrence Mayer 17
William Morley and Caroline Trahan In honor of Kyle Trahan
The Multiple Myeloma Research Foundation
Jinnah Phillips, M.D. 5
Radiological Society of North America 9
Sunny Raspet 5
Robert E. Roberts, Ph.D. 9
In memory of Anita Roberts
Charles A. Sanders, M.D. and Ann E. Sanders 21
Joshua Sasouness In honor of Rod Hubbard
Matthew Scher and Barbara Lazio In memory of Barbara L. Lazio, Carol Scher and Jane Scher
Sullivan & Cromwell LLP
Ullmann Family Foundation 18
WellMed Charitable Foundation
The Richard H. Yearick Foundation 19
Elias A. Zerhouni, M.D. and Nadia Zerhouni, M.D. 5
Carole Snow 5
Sara Lou Whildin 5
Steve and Chris Wilsey 9

$2,500–$4,999

Marc and Anita Abramowitz 2
The Beckman Research Institute of City of Hope, Department of Population Sciences, Division of Nursing Research and Education
Ronald and Barbara Berke 5
In memory of Jenny Berke
Facebook 1
Chris and Laura C. Hazzard 9
In memory of Richard Curtin
William E. and Louise A. Hess 1
W. Seymour Holt, M.D. and Rheta Holt 7
Julie Bell Lindsay 1
In memory of T. Douglas Lindsay
Catherine Master 1
In honor of Larry Doll, Ann Halverson, Mo Henderson, Betty Parker and Steve Seifert
James Muldoon
Oncology Nursing Society
PTA Jankowski Charitable Fund 3
Alan S. Rabson, M.D. 2
Linda P. Reed 1
John and Katrina Rogers 3
In memory of Brenda S. Jones
Steven L. and Karin Siegel 2
The Honor Society of Nursing, Sigma Theta Tau International (STTI)
SunTrust Banks, Inc. 2
Samuel O. Thier, M.D. and Paula Thier 12
Sara Lou Whildin 5
Steve and Chris Wilsey 9
Anonymous (3)  
Kimberly Allen  
Apple Inc.  
John and Sandra Atkins  
Dr. Nadarajah Balasubramanian  
Robert Balthaser and Ricardo C. Araneda, Ph.D.  
Frederick C. and Rebecca B. Becker  
Joe Bergera and Alice S. Cho  
Zachary T. Bloomgarden, Ph.D. and Kathy F. Bloomgarden, Ph.D.  
Christopher J. Boyd and Jamie N. Cooper  
Brian V. Breheny and Pedro Lay  
In memory of T. Douglas Lindsay  
Marc and Debbie Breslawsky  
Ambassador and Mrs. Dwight L. Bush, Sr.  
Calibre Systems Inc  
Calico Labs  
Charles Cerf and Cynthia E. Dunbar, M.D.  
Ken Chang  
Clark Family Gifting Trust  
Craig and Susan Clendening  
Daniel Cunningham and Mary Hennessey  
Max Delgadillo  
Deloitte Consulting LLP  
Alicia Emerson  
In memory of Scott Emerson  
FS Networks  
Faith United Methodist Church  
Friedman Family Gift Fund  
In memory of Ruth Friedman  
James and Karen Gavic  
Stanley and Eve Geller  
Eileen Grams  
Margaret Grieve  
In memory of Nina K. Solarz and in memory of Stephen J. Solarz  
Rizwan H. Habeeb, M.D.  
Paul Heider  
Dr. and Mrs. Paul L. Herrling  
IQ Solutions  
Jean Janklow Estrin  
Laura Jansen  
Arthur H. and Jean B. Jerbert  
Alex Johnson, Ph.D.  
Bernard H. and Georgina E. Kaufman  
Kevin and Teresa Klock  
In memory of Fred and Helen Balding  
William Knowlton  
In memory of Linda Knowlton  
Jeremy Krasner  
Arnold Lakind  
Sherry Lansing and William Friedkin  
Howard H. and Jacqueline K. Levine  
In memory of Stephen J. Solarz  
Jonathan D. Levine  
John Madden, Jr.  
Margaret and James Malaro  
Marriott International  
Patrick and Barbara McGarey  
Raymond Michael  
Nabil A. Moufarrej, M.D.  
Navitor Pharmaceuticals  
Donna Nichols  
In honor of Mattison C. Painter  
Omega World Travel Inc.  
Matthew W. O’Neill and Erica Joyce Lam  
In memory of Dean R. O’Neill  
Susanne N. O’Neill  
In memory of Dean R. O’Neill  
Matt and Robyn Nichols Painter  
Paragon Pharmaceuticals  
Carl L. Quinn  
Cheryl M. Rakestraw  
Jane Robinson  
Gregory and Sherry Roper  
Robert and Marjorie Rosenberg  
Stanley O. Roth  
Saks Fifth Avenue  
Lenore R. Salzman  
In memory of Norman P. Salzman  
Richard I. and Anastasia Smith  
Sobi, Inc.  
Dr. Ann K. Syrdal  
Andrew Traficanto  
The Drs. Tremoulet  
Jon and Kristin Vaver  
Mr. Mehdi Nafissi and Dr. Ann F. Welton  
David Wholley  
Stewart K. Wilson  
In memory of Blaise Ribet, Alan Wilson, Beulah Wilson and Christina Wilson  
Wolzinger Family Foundation  
Richard G. Wyatt, M.D. and Linda S. Wyatt, Ph.D.  
Lucas and Katrina Yun-Nikolic  
Daniel Zhao  
In memory of Michelle
Anh Do ∞
In honor of Khanh Tu and H. Tran

Ronald Early ∞
Michael Erickson

James M. Felser, M.D. ∞
In memory of Stephen E. Straus

Nicholas M. and Jacqueline E. Ferrer ∞
Jeffrey and Marilyn Finn

Keith Gendler ∞
Gene and Esther Gorman

Randall and Holly Griffin
In memory of Brian Griffin

Joe Grossman ∞
Ken and Yvette Guidry

Joyce B. Harp, M.D. ∞
William Harris, M.D.

Kay A. Hart ∞
Thomas H. and Rita R. Hassall ∞

Healthy Directions LLC

Kelley Hearne
In memory of T. Douglas Lindsay

Eric Hirschhorn and Leah Wortham
In memory of Stephen J. Solarz

Girard and Pauline Ann Histed
In honor of Pauline Ann Histed

The Martha B. and Michael S. Horne Charitable Fund

Susan C. Horowitz ∞
In memory of Arthur G. Horowitz

Harold Huston ∞
In honor of Laura Huston

Terrance J. Jach and Paula J. Warrick

James F. and Gudrun Jeffrey ∞

Robert S. and Raissa H. Johnson ∞

Richard Jonas and Katherine Vernot-Jonas ∞

Michael M. Kaback, M.D. ∞

Gurdyal Kalsi, M.D.

Charles E. Kaufman Medical Fund

Ronald L. Kral, M.D. and Susan J. Kral ∞

Kumar Family Charitable Fund

Ann Lemmon ∞

Ron Levenbaum, D.M.D. ∞

Ahmed Mahmoud ∞

Marathon Asset Management

Robert F. Marino ∞
In memory of Frank and Juanita Marino

Cathleen Martin ∞
The Honorable Matthew McHugh

Donna Mckelvey

Ari and Abbey Meltzer

Allen Morris and Barbara Bissell

Steven and Kimberlee Owens

Netflix ∞

Kenneth W. Odom ∞

Gilbert S. Omenn, M.D., Ph.D. and Martha A. Darling ∞

Steven and Kimberlee Owens

In memory of Laurie Kemna & L. D. Reynolds

Farhan Panthaki ∞

Marilyn H. Paul ∞

Robert and Paula Pettersen ∞

Anne Pfaelzer De Ortiz ∞

Eric F. Polhaus ∞

The Relias Family ∞

Johng S. Rhim, M.D. ∞

Lorene Steinberg

In memory of Steven Steinberg

Christopher and Elizabeth Thoma ∞

William, Zani and Ayce Tolentino ∞

Claire E. Toth
In honor of Carol-Ann Harris

Anne S. Tsukuda ∞

Eugene J. Van Scott, M.D. ∞

Paula J. Warrick, Ph.D. ∞

Robert C. Watson and Debra D. Petersen ∞

West American Rubber Company, LLC
In memory of Harold L. Slucher

Julie and Howard Wolf-Rodda ∞

Steven Wong ∞

Brett Wood ∞

Dr. Stuart H. Yuspa and Eleanor H. Yuspa ∞
Anonymous (4)
Amazon Smile Foundation 4
American Express Company 3
Jeffrey and Ann Anderson
Diego Ardila In honor of Laura Ardila
Miriam Archo
Stephen D. and Margie C. Ban In honor of Sophia Trujillo
Jill H. Barr 9 In memory of John L. Barr
Ann Beck 10
Joan Beck 7
Stuart J. and Ruth Brahns 3
Dana Bresin In honor of Laura C. Hazzard
Ryan Brown In memory of Brian Griffin
Martin J. Corso, M.D. 2
Mary Frances Cotch and B. Fenton Hall
Daniel Czamecki
Rosemary Dawicki
Larry Day 2
Jeffrey J. Doenges 3
Marguerite Durkin 2
Jeffrey Dwoskin 4
Faye Fager 4
Arlene L. Feit 3
Michelle M. Frack
David A. Fryburg, M.D. 6
Daniel T. and Amy Moore Gallmeyer Gartner, Inc.
Jason and Gloria Garver 11
Thomas Gasparini
Margaret Gavin 2
Dr. Martin Gellert
Peggy J. Gerlacher 20 In memory of John D. Gerlacher
Michael Gottlieb, Ph.D. and Joan Gottlieb 4 In honor of the Staff of the Foundation for the National Institutes of Health
Sam D. Graham, M.D. and Jane O. Graham 7
Gerald Haley
Eric J. and Susan Hatch
Chris Hauck In memory of Mary L. Rhim
Robert Heady
Henry L. Hecht In honor of Stuart H. Yuspa
D. Henderson
Greg and Sally Henderson In honor of Christene Kazanas
Eva C. Holtz 2
James Horton, M.D. 3
Howard County General Hospital In memory of Brian Griffin
Kathleen M. Hunn
Intel Corporation
George Isaac
Raymond James 2
Youngmi Ji, Ph.D. In memory of Mary L. Rhim
Norris Johnson In memory of Timothy J. Johnson
Chien Yuan Kao
Samantha Kaplan 5
Anne Kelly 2
John A. Kennedy 2
Amanda Kirk
Paul and Nancy Kurland 1
Brian Ladd
Thomas A. and Nancy I. Lusk
Greg Lytle In memory of Mary L. Rhim
Dr. Adel A. Mahmoud and Dr. Sally Hodder
Anne Alexander Marshall, Ph.D. and Davis Marshall 13
Travis McCaw
Microsoft Corporation 2
Stephen A. Migueles
Gloria Monarrez 2
Jorge Morazzani 4
Jonathan Moskow
Susan M. Nebinski In memory of Stan C. Nebinski
Benjamin S. and Elizabeth F. Neufeld, Ph.D. 2
Byong Park
Nora Phillips
Christopher Pike In memory of Thomas Pike
Timothy Ponden 3
William J. Price 8
Jacqueline Ratner
Arnold C. Rausch and Renee Puzio 3
Robert Rea
Sangam V. Reddy
Michael J. Richman 2
James and Lora Rodenberg 2 In memory of Dennis Rodenberg
Judy Rose In memory of Mary L. Rhim
Sidney Rosenzweig 4
Walter G. Rostykus and Catherine Elliott-Rostykus
Michael Roytburd 2
Janice W. Rutherford 3
Dr. Michael Ryan and Dr. Linda Ryan 1
Darren Schneider 3
Mary Jo Shapiro
Richard and Elizabeth Slucher In memory of Harold L. Slucher
Rainer F. Storb, M.D.
Anthony Tassone 5
Harold E. Varmus, M.D. 2
David Vigil
Matthew Warnecke
Theodore Wells 2
Wiley Rein LLP 2
Ingrid Wiley 9
Xcel Energy Inc.
Joyce A. Yarington 14 In memory of Lila Wilson
Joel Yesley 10
### Financial Highlights

#### Revenue and Support

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$58,518,484</td>
<td>$80,605,604</td>
</tr>
<tr>
<td>Grants</td>
<td>381,969</td>
<td>351,613</td>
</tr>
<tr>
<td>Administrative fee</td>
<td>111,660</td>
<td>122,392</td>
</tr>
<tr>
<td>Government appropriations</td>
<td>1,110,000</td>
<td>1,150,000</td>
</tr>
<tr>
<td>Investment earnings</td>
<td>2,443,260</td>
<td>1,102,491</td>
</tr>
<tr>
<td>In-kind contributions</td>
<td>1,490,818</td>
<td>960,688</td>
</tr>
<tr>
<td>Donated services</td>
<td>39,000</td>
<td>30,000</td>
</tr>
<tr>
<td>Fundraising event</td>
<td>324,700</td>
<td>279,800</td>
</tr>
<tr>
<td><strong>Total revenue and support</strong></td>
<td><strong>$64,419,891</strong></td>
<td><strong>$84,602,588</strong></td>
</tr>
</tbody>
</table>

#### Expenses and changes in net assets

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Program services</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fellowships and training programs</td>
<td>$958,145</td>
<td>$1,257,933</td>
</tr>
<tr>
<td>Memorials, awards and events</td>
<td>813,509</td>
<td>390,128</td>
</tr>
<tr>
<td>Capital projects</td>
<td>66,782</td>
<td>51,627</td>
</tr>
<tr>
<td>Research programs</td>
<td>49,897,652</td>
<td>41,957,442</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td><strong>$51,736,088</strong></td>
<td><strong>$43,657,130</strong></td>
</tr>
<tr>
<td><strong>Supporting services</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and general</td>
<td>$4,986,112</td>
<td>$3,800,393</td>
</tr>
<tr>
<td>Fundraising</td>
<td>438,402</td>
<td>392,283</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td><strong>$5,424,514</strong></td>
<td><strong>$4,192,676</strong></td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$57,160,602</strong></td>
<td><strong>$47,849,806</strong></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$7,259,289</td>
<td>$36,752,782</td>
</tr>
<tr>
<td>Net assets beginning of year</td>
<td>103,228,330</td>
<td>66,475,548</td>
</tr>
<tr>
<td><strong>Net assets at end of year</strong></td>
<td><strong>$110,487,619</strong></td>
<td><strong>$103,228,330</strong></td>
</tr>
</tbody>
</table>
Board of Directors
As of December 2017

Officers

Steven M. Paul, M.D.
CHAIRMAN

Maria C. Freire, Ph.D.
PRESIDENT AND EXECUTIVE DIRECTOR

Solomon H. Snyder, M.D.
VICE CHAIRMAN

Steven C. Mayer
TREASURER

Mrs. William McCormick Blair, Jr.
SECRETARY

Elected Directors

Kathy Bloomgarden, Ph.D.
Buffy Cafritz
James H. Donovan
Paul L. Herrling, Ph.D.
Thomas R. Insel, M.D.
Judy Lansing Kovler, Ph.D.
Ronald L. Krall, M.D.
Freda C. Lewis-Hall, M.D., DFAPA
Edison T. Liu, M.D., Ph.D.
Joel S. Marcus
Paul M. Montrone, Ph.D.
Martin J. Murphy Jr., Ph.D.,
DMedSc, FASCO
Jillian Sackler, D.B.E.
Lily Safra
Charles A. Sanders, M.D.
Fred Seigel
Ellen V. Sigal, Ph.D.
Nina K. Solarz
Russell W. Steenberg
Paul Stoffels, M.D.
Samuel O. Thier, M.D.

Ex Officio

Francis S. Collins, M.D., Ph.D.
Scott Gottlieb, M.D.

Directors Emeritus

Paul Berg, Ph.D.
Sherry Lansing
The Honorable
John Edward Porter

Honorary Directors

Luther W. Brady, M.D.
Ann Lurie
Patrick C. Walsh, M.D.